A problem is to provide a method of inhibiting nonspecific reaction unique to feces in a detection method using immunochromatography developing a fecal sample in an insoluble membrane so as to detect an analyte in the sample, and an immunochromatographic test strip used therefor. The present invention provides a method of performing an immunochromatographic reaction in the presence of an anti-IgA antibody so as to detect an analyte in a fecal sample without being affected by nonspecific reaction, and an immunochromatographic test strip used therefor.

The present invention relates to monoclonal antibodies targeting the membrane bound IgM (mIgM) of the B-cell receptor complex found in B-cell lymphomas and leukemias. Monoclonal antibodies designated mAb4-2b, mAb1-1, mAb2-2b and mAb3-2b were produced by hybridoma cell lines (ATCC deposit no. PTA-121716), (ATCC deposit no. PTA-121719), (ATCC deposit no. PTA-121717), and (ATCC deposit no. PTA-121718), respectively. Another aspect of the present invention is the use of anti-B-Cell mIgM antibodies in the treatment of B-cell malignancies, including B-cell lymphomas and leukemias.

Provided are a liquid formulation of long-acting insulinotropic peptide conjugate, containing a pharmaceutically effective amount of long-acting insulinotropic peptide conjugate consisting of a physiologically active peptide, insulinotropic peptide, and an immunoglobulin Fc region; and an albumin-free stabilizer, wherein the stabilizer comprises a buffer, a sugar alcohol, and a non-ionic surfactant, and a method for preparing the formulation. For the purpose of preventing microbial contamination, a preservative may be added. The liquid formulation of the present invention is free of human serum albumin and other potentially hazardous factors to body, having no risk of viral contamination, and thus can provide excellent storage stability for insulinotropic peptide conjugates at high concentration.

The present invention provides a method of treating, delaying the onset, delaying progression of, reducing the incidence of or reducing the severity of amyotrophic lateral sclerosis in a subject, the method comprising administering to a subject an agent, which interferes with IgG-A2BG2 expression, IgG-A2BG2 function or IgG-A2BG2 interaction with CD16 in said subject.

The invention provides anti-polymeric IgA (plgA) antibodies and methods of using the same.

The current invention is directed to an antibody comprising at least four binding sites specifically binding to an immunoglobulin Fc-region of the human IgG1 subclass comprising one, two, three or four amino acid changes compared to a wild-type Fc-region of the human IgG1 subclass for use as positive control and calibration standard in an immunoassay for the detection and quantification of anti-drug antibodies against said one, two, three or four amino acid changes in the Fc-region of the drug antibody.

IgG epitope and applications thereof as a target are provided. The IgG epitope is the C.sub.H1 domain of non-B cell-derived IgG, and there is N-glycosylated sialic acid modification at the Asn162 site of the domain. The realization of its antigen functions must depend on the sialylation of the site. The present invention further discloses the applications of the IgG epitope as a drug target in preparing drugs for diagnosis and/or treatment of epithelial tumors. In addition, our studies showed that this antigen depends on the sialylation of Asn162 site as a drug target, and the sialylation of this site must depend on sialyltransferase ST3GAL4, indicating that the enzyme can be used as a drug target for preparing tumor therapeutic drugs. Further, integrin 4 is co-expressed and co-localized with IgG containing the epitope. IgG can be used as a marker for preparing drugs for the auxiliary detection of epithelial tumors.

A platform technology provides particle and nucleic acid conjugates, and compositions thereof, with enhanced targeting to cells, tissues, organs. The particles and nucleic acids and other deliverables contain a synthetic binding protein such as a polypeptide monobody covalently conjugated to the surface of the particle or the nucleic acid, for linking a targeting agent to the particle's surface or the nucleic acid. The particles and nucleic acids and other deliverables optionally contain an antibody non-covalently conjugated to the binding protein, via an Fc domain of the antibody. The particles can include therapeutic agents, diagnostic agents, prophylactic agents, or a combination thereof, to be delivered to desired cells, tissues, and/or organs. The particles and nucleic acids and other deliverables can be used in a wide array of applications including, but not limited to, ex vivo perfusion of mammalian organs and in vivo disease treatment.

In certain aspects, the disclosure relates to anti-idiotype antibodies and antigen-binding portions thereof that specifically bind a KL2B413 containing protein, e.g., an antibody or antigen-binding portions thereof. In some aspects, the anti-idiotype antibodies and antigen-binding portions of the present disclosure can be used in methods to detect and quantify cells expressing chimeric antigen receptors that include KL2B413.

Provided are methods of diagnosing IgA nephropathy in a subject. Optionally, the methods comprise isolating an IgG from the subject and determining whether the IgG binds to a galactose-deficient IgA1. Optionally, the methods comprise providing a biological sample from the subject and detecting in the sample a mutation in a IGH gene, wherein the mutation is in a nucleotide sequence encoding a complementarity determining region 3 (CDR3) of a IGH variable region. Optionally, the methods comprise determining a level of IgG specific for a galactose-deficient IgA1 in the subject. Also provided are methods of treating or reducing the risk of developing IgA nephropathy in a subject.